Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.58 |
| ▸ | GNRHR | P30968 | 6/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931223 | 0.90 | CHRM1 (0.58) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL12376469 | 0.85 | CHRM1 (0.53) | CHRM1GNRHRP2RX3KMT2AALDH1A1 | |
| SCHEMBL14922852 | 0.82 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1550419 | 0.82 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1550162 | 0.82 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1931562 | 0.81 | CHRM1 (0.48) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1931415 | 0.81 | CHRM1 (0.48) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1931549 | 0.81 | CHRM1 (0.48) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL1931435 | 0.81 | CHRM1 (0.48) | CHRM1GNRHRP2RX3KMT2AKDM4E | |
| SCHEMBL7921098 | 0.80 | CHRM1 (0.48) | CHRM1P2RX3KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312949-B1 | N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010019391-A1 | N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, OPRM1 | CHRM1 1/4885GNRHR 591/4885P2RX3 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.